Key result
Beta-blockers for acute myocardial infarction probably reduce short-term reinfarction (RR 0.82; 98% CI 0.73-0.91) and long-term all-cause mortality (RR 0.93; 97.5% CI 0.86-0.99) compared to placebo.
Why the study?
Previous meta-analyses on beta-blockers for acute myocardial infarction showed conflicting results ranging from harms, neutral effects, to benefits, and no systematic review using Cochrane methodology had assessed them.
Do beta-blockers reduce mortality and cardiovascular events in people with suspected or diagnosed acute myocardial infarction?
Population
85,550 participants (mean age 57.4 years) across 63 trials with suspected or diagnosed acute myocardial infarction
Comparison
Beta-blockers vs placebo or no intervention
Design
Systematic review and meta-analysis of randomised clinical trials
Follow-up
Primary time point less than three months, and maximum follow-up beyond three months
Authors
Loading...
Beta-blockers merit routine consideration in acute MI; reinforces consensus on reinfarction and mortality reduction with updated synthesis.
Meta-Analysis (n=85,550)
Do beta-blockers reduce mortality and cardiovascular events in people with suspected or diagnosed acute myocardial infarction?
Effect estimate: RR 0.94 (95% CI 0.90 to 1.00)
Beta-blockers for suspected or diagnosed acute myocardial infarction probably reduce the short-term risk of reinfarction and the long-term risk of all-cause and cardiovascular mortality.
Safi et al. (2019) conducted a meta-analysis in suspected or diagnosed acute myocardial infarction (n=85,550). Beta-blockers vs. Placebo or no intervention was evaluated on All-cause mortality at less than three months (RR 0.94, 95% CI 0.90 to 1.00). Beta-blockers for acute myocardial infarction probably reduce short-term reinfarction (RR 0.82; 98% CI 0.73-0.91) and long-term all-cause mortality (RR 0.93; 97.5% CI 0.86-0.99) compared to placebo.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: